| Literature DB >> 31988653 |
Yu Gao1, Fengxue Wang1, Yanjun Song1, Haibo Liu1.
Abstract
Berberine has significant antibacterial and antipyretic effects and is a commonly used drug for treating infectious diarrhoea. The current research data show that the pharmacological effects of berberine are numerous and complex, and researchers have been enthusiastic about this field. To allow researchers to quickly understand the field and to provide references for the direction of research, using bibliometrics, we analysed 1426 articles, dating from 1985 to 2018, in the field of berberine pharmacology. The research articles we found came from 69 countries/regions, 1381 institutions, 5675 authors, and 325 journals; they contained 3794 key words; they were written in 7 languages; and they were of 2 article types. This study summarizes and discusses the evolution of the historical themes of berberine pharmacology as well as the status quo and the future development directions from a holistic perspective.Entities:
Keywords: Berberine; Bibliometrics; CiteSpace; Evolutionary trend; Pharmacology; Web of Science
Year: 2020 PMID: 31988653 PMCID: PMC6971869 DOI: 10.1186/s13020-020-0288-z
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 5.455
Fig. 1The structure of berberine
Fig. 2Research flow chart of the study
Fig. 3Yearly output and score
Fig. 4Distribution of global publications in the field of berberine pharmacology
Fig. 5The percentage of articles in the top ten countries
Fig. 6Map of cooperative networks among countries, researchers and institutions. a Academic cooperation networks between countries/regions. b Academic cooperation networks between authors. c Academic cooperation networks between institutions
The top 10 institutions (based on records and TGCS respectively)
| Institution | Records | Institution | TGCS |
|---|---|---|---|
| China Pharmaceut Univ | 71 | China Pharmaceut Univ | 1454 |
| Chinese Acad Sci | 34 | Natl Yang Ming Univ | 923 |
| Shanghai Univ Tradit Chinese Med | 34 | China Med Univ | 763 |
| China Med Univ | 30 | Seoul Natl Univ | 732 |
| Chinese Acad Med Sci | 29 | Univ Macau | 683 |
| Second Mil Med Univ | 26 | Univ Hong Kong | 631 |
| Kyung Hee Univ | 25 | Kyung Hee Univ | 627 |
| Shenyang Pharmaceut Univ | 25 | Panjab Univ | 580 |
| Beijing Univ Chinese Med | 24 | Shanghai Univ Tradit Chinese Med | 575 |
| Nanjing Univ Chinese Med | 24 | Shanghai Jiao Tong Univ | 563 |
| Chinese Univ Hong Kong | 563 |
The top 9 authors
| Name | Institution | H-index | G-index | Records | TGCS |
|---|---|---|---|---|---|
| Chen L | Sun Yat-Sen University | 15 | 21 | 21 | 467 |
| Wang Y | Shenyang Pharmaceutical University | 13 | 20 | 29 | 450 |
| Zhang Y | Jilin University | 12 | 17 | 24 | 331 |
| Wang GJ | China Pharmaceutical University | 12 | 16 | 16 | 665 |
| Ma YM | Shanghai University of Traditional Chinese Medicine | 11 | 17 | 20 | 301 |
| Li XG | Southwest University | 11 | 15 | 15 | 323 |
| Liu XD | China Pharmaceutical University | 11 | 12 | 12 | 533 |
| Li J | China Pharmaceutical University | 10 | 16 | 20 | 286 |
| Ye XL | Southwest University | 10 | 13 | 13 | 285 |
The top 10 journals
| Rank | Journal | ISSN | Recs | TGCS | IF (2018) |
|---|---|---|---|---|---|
| 1 | 0378–8741 | 82 | 2816 | 3.414 | |
| 2 | 0014–2999 | 59 | 2088 | 3.170 | |
| 3 | 0731–7085 | 56 | 1483 | 2.983 | |
| 4 | 0951–418X | 49 | 1545 | 3.766 | |
| 5 | 0032–0943 | 49 | 1431 | 2.746 | |
| 6 | 0918–6158 | 48 | 1730 | 1.540 | |
| 7 | 0944–7113 | 47 | 1303 | 4.180 | |
| 8 | 1671–4083 | 45 | 924 | 4.010 | |
| 9 | 0753–3322 | 34 | 344 | 3.743 | |
| 10 | 0367–326X | 33 | 869 | 2.431 |
Fig. 7Timeline view for document co-citation clusters
The specific situation of 12 clusters
| Cluster ID | Size | Silhouette | Mean year | Cluster label |
|---|---|---|---|---|
| 0 | 46 | 0.747 | 2008 | Gata |
| 1 | 46 | 0.66 | 2007 | Pharmacokinetics |
| 2 | 44 | 0.793 | 2000 | Coralyne |
| 3 | 31 | 0.941 | 1995 | Antipyretic |
| 4 | 31 | 0.867 | 2014 | Pi3k-akt |
| 5 | 30 | 0.788 | 2006 | Reactive oxygen species |
| 6 | 24 | 0.839 | 2008 | Erk signaling pathway |
| 7 | 23 | 0.817 | 2012 | Neuroinflammation |
| 8 | 17 | 0.813 | 2003 | Vascular smooth muscle cell |
| 9 | 14 | 0.903 | 2010 | Hypoglycemic |
| 10 | 10 | 0.889 | 1999 | Therapeutic effect |
| 11 | 8 | 0.934 | 1997 | Superoxide dismutase |
Key articles in each cluster
| Cluster | Coverage | TGCS | Title | First author | Journal | Year |
|---|---|---|---|---|---|---|
| 0 | 14 | 34 | Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study | LIU, L | 2010 | |
| 1 | 13 | 17 | Pharrnacokinetic properties, potential herb-drug interactions and acute toxicity of oral rhizoma coptidis alkaloids | MA, BL | 2013 | |
| 2 | 10 | 30 | Protoberberine alkaloids: physicochemical and nucleic acid binding properties., V10, P55 10.1007/7081_2007_071 | MAITI, M | 2007 | |
| 3 | 5 | 226 | A comparative study on the anti-inflammatory, antinociceptive and antipyretic effects of isoquinoline alkaloids from the roots of turkish berberis species | KUPELI, E | 2002 | |
| 4 | 9 | 4 | Identification of actin as a direct proteomic target of berberine using an affinity-based chemical probe and elucidation of its modulatory role in actin assembly | YI, CM | 2017 | |
| 5 | 7 | 13 | Selective regulation of multidrug resistance protein in vascular smooth muscle cells by the isoquinoline alkaloid coptisine | SUZUKI, H | 2010 | |
| 6 | 7 | 28 | Involvement of mitochondrial and b-raf/erk signaling pathways in berberine-induced apoptosis in human melanoma cells | BURGEIRO, A | 2011 | |
| 7 | 9 | 23 | Role of berberine in alzheimer’s disease | CAI, ZY | 2016 | |
| 8 | 5 | 121 | Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1 beta and inducible nitric oxide synthase in the rat model of alzheimer’s disease | ZHU, FQ | 2006 | |
| 9 | 5 | 80 | Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies | PIRILLO, A | 2015 | |
| 10 | 7 | 10 | Blockade of l-type calcium channel in myocardium and calcium-induced contractions of vascular smooth muscle by cpu 86017 | DAI, DZ | 2004 | |
| 11 | 3 | 54 | Coptidis rhizoma: protective effects against peroxynitrite-induced oxidative damage and elucidation of its active components | YOKOZAWA, T | 2004 |
Fig. 8Word cloud of the top 50 words
Fig. 9The words from the burst detection
Main clinical application and mechanism of berberine
| Clinical application | Mechanism | Literature |
|---|---|---|
| Anti-diarrheal | Antibacterial (e.g., Vibrio cholerae) Inhibition of intestinal smooth muscle movement regulates intestinal motility Inhibition of intestinal mucosa K+’s influx restores intestinal barrier function | [ |
Anticancer (cancer arising from leucocytes, liver, lung, stomach, colon, skin, oral, etc.) | Chemical carcinogenic protection Independent of the mevalonate pathway Directly induces apoptosis Downregulation of nuclear transcription factors Exertion of indirect effects Suppression of DNA | [ |
| Anti-diabetic | Stimulation of AMPK activity and might inhibit PPARγ activity Promotion of the proliferation of 3T3-L1 pre-adipocytes, reduced lipid accumulation, and inhibition of their differentiation Insulinotropic effects Good action for lipid metabolism Targeting of non-coding RNAs Promotion the expression of GLUT1 Modulation of the gut microbiota | [ |
Anti-cardiovascular (e.g., Atherosclerosis) | Inhibition of the expression of LOX-1 through ET-1 receptors Impacts on potassium ion channels (K +) Increased NO and cGMP content Blockage of K + channels sensitive to ATP and voltage Inhibition of mitogen-activated kinase/extracellular signals | [ |
Anti-inflammatory and immune regulation (e.g., ulcerative colitis) | Inhibit cox-2, AP-1 binding Downregulation of activation of ERK 1/2 and p38 signallings pathways, Inhibition of the production of pro-inflammatory factors Downregulation of p-ERK, p-p38, and p-JNK activation Inhibition of the expression of monocyte chemoattractant protein 1 and cytokine-induced neutrophil chemoattractant 1 induced by lipopolysaccharide Inhibition of RNA virus reverse transcriptase activity Inhibition of the synthesis of anti-SRBC antibodies Reduced content of PGF2a in inflammatory tissues | [ |
Antipsychotic (e.g., depression, Alzheimer’s,) | Increased NE and 5-HT concentrations in the brain Promotion of axon extension and axon regeneration in PNS-damaged nerves Increased expression of BDNF mRNA in the hippocampus Actions on the pathological process of amyloid Aβ, inhibitings glial proliferation Inhibition of tau hyperphosphorylation induced by calmodulin A and its induced cytotoxicity Inhibition of MAO activity | [ |